Reprogramming cancer’s survival logic
NextAge is building therapies designed to restore vulnerability in resistant cancers by targeting adaptive stress programs that enable persistence, relapse, and treatment failure.
The problem
Cancer adapts under pressure
Even effective therapies select for cells that can tolerate stress and persist.
Resistance is systematic
Relapse often reflects adaptive survival programs—not a single missed mutation.
Durable responses are rare
To change outcomes, we must address survival circuitry that supports persistence.
Our approach
NextAge targets cellular stress tolerance—mechanisms that allow cancer cells to remain viable under hypoxia, genotoxic stress, and therapy. By dismantling these adaptive programs, we aim to restore fragility to cells that have become resistant to conventional treatment.
Platform-led discovery
Identify actionable control nodes that govern survival under stress.
Combination-ready biology
Designed to pair with standard-of-care therapies to prevent escape.
Translational focus
Built for clear biomarkers and clinically meaningful endpoints.
Platform, not a single asset
NextAge is building a discovery engine for developing first-in-class therapeutic programs that disrupt adaptive survival systems. This platform enables multiple programs across tumor contexts while preserving optionality in indication and combination strategy.
Why now
Precision oncology transformed targeting, but adaptation remains an unsolved layer. NextAge is addressing the stress-response biology that underlies persistence and therapy resistance.
Selected scientific visuals
Two representative visuals from internal presentations. Additional figures available upon request.
Our vision
We believe cancer can be forced back into fragility.
Not by hitting it harder — but by removing its ability to adapt.
Through first-in-class therapeutic programs, we are building new ways to restore vulnerability in resistant cancer cells.